<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285505</url>
  </required_header>
  <id_info>
    <org_study_id>A6131020</org_study_id>
    <nct_id>NCT01285505</nct_id>
  </id_info>
  <brief_title>Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation</brief_title>
  <official_title>Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To An Alprazolam Sublingual Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the hypothesis that the bioavailability of alprazolam from a new sublingual
      formulation is the same as that from an existing sublingual formulation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alprazolam bioavailability as assessed from the area under the concentration-time curve (AUC)</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alprazolam bioavailability as assessed by peak concentration (Cmax)</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alprazolam time of maximum concentration (Tmax)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life of alprazolam</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant safety laboratory tests</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant adverse events</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant vital signs</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Alprazolam commercial sublingual tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alprazolam test sublingual tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alprazolam commercial sublingual formulation</intervention_name>
    <description>0.5 mg tablet, single dose</description>
    <arm_group_label>Alprazolam commercial sublingual tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alprazolam test sublingual tablet</intervention_name>
    <description>0.5 mg tablet, single dose</description>
    <arm_group_label>Alprazolam test sublingual tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male or female subjects

          -  BMI 18 to 26.9

          -  must give informed consent

        Exclusion Criteria:

          -  clinically significant disease

          -  narrow angle glaucoma

          -  positive drug screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6131020&amp;StudyName=Bioequivalence%20of%20a%20new%20and%20a%20commercial%20alprazolam%20sublingual%20formulation</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2011</study_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>alprazolam</keyword>
  <keyword>sublingual</keyword>
  <keyword>bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

